Class Broad-spectrum chemokine inhibitor

Structure N-substituted aminocaprolactam

Properties BN83470 is a potent inhibitor of chemokine-induced leukocyte migration in vitro (EC50 = 0.1nM) and LPS-induced leukocyte recruitment in vivo (ED50 = 0.002 mg/kg). It is orally active (~80% bioavailable) and has pharmacokinetics optimised for once-a-day dosing.

Target indication(s) BN83470 will initially be developed for respiratory indications, including asthma, allergic rhinitis and ultimately COPD.

Status Preclinical.

Class Broad-spectrum chemokine inhibitor

Structure N-substituted aminocaprolactam

Properties BN83250 is a potent inhibitor of chemokine-induced leukocyte migration in vitro (EC50 = 0.09nM) and LPS-induced leukocyte recruitment in vivo (ED50 = 0.0003 mg/kg). Although it has some oral bioavailability, it is optimised for parenteral delivery (intravenous or local administration). BN83250 has been shown to inhibit surgical adhesion formation (>90%) in preclinical models.

Target indication(s) BN83250 will be developed for the prevention of surgical adhesions, initially in a gynecological setting.

Status Preclinical.

Dr David Fox was the founding partner of The Cambridge Partnership. He is a British Heart Foundation Senior Fellow in the Department of Medicine, Cambridge University based at Addenbrooke’s Hospital.

As the Principal Investigator of the Inflammation Research & Therapy Laboratory he specialises in the pathogenesis of lorem...

Dr John S.Beec was the founding partner of The Cambridge Partnership. He is a British Heart Foundation Senior Fellow in the Department of Medicine, Cambridge University based at Addenbrooke’s Hospital.

As the Principal Investigator of the Inflammation Research & Therapy Laboratory he specialises in the pathogenesis of lorem...